Finnish gelsolin amyloidosis causes significant disease burden but does not affect survival: FIN-GAR phase II study | Orphanet Journal of Rare Diseases | Full Text

Finnish gelsolin amyloidosis causes significant disease burden but does not affect survival: FIN-GAR phase II study | Orphanet Journal of Rare Diseases | Full Text

Finnish gelsolin amyloidosis causes significant disease burden but does not affect survival: FIN-GAR phase II study

Hereditary gelsolin (AGel) amyloidosis is an autosomal dominantly inherited systemic amyloidosis that manifests with the characteristic triad of progressive ophthalmological, neurological and dermatological si...

Authors:Eeva-Kaisa Schmidt, Tuuli Mustonen, Sari Kiuru-Enari, Tero T. Kivelä and Sari Atula

Citation:Orphanet Journal of Rare Diseases 2020 15:19

Content type:Research

Published on: 17 January 2020

• ViewFull Text
 
• ViewPDF